Point Mutations of the RUNX1/AML1 Gene in Sporadic and Familial Myeloid Leukemias
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
TheRUNX1/AML1 gene is known to be the most frequent target for chromosomal translocation in leukemia. In addition, recent studies have demonstrated point mutations in theRUNX1 gene as an another mode of genetic lesion resulting in leukemia. Of particular interest, sporadic point mutations of biallelic type are found in a tight association with either the acute myelogenous leukemia (AML) M0 subtype or trisomy 21. Germline mutations give rise to a familial platelet disorder that results in a predisposition to acute myelogenous leukemia (FPD/AML). Most of the RUNX1 mutants were defective in DNA binding but still active in β binding, a characteristic that is consistent with the 3-dimensional structural findings and may explain the dominant inhibitory effects. Although genuine haploinsufficiency of RUNX1 was observed in some cases, a greater majority of mutant RUNX1 proteins may also act in a dominant-negative manner, possibly creating a higher propensity for leukemia development. The stronger dominant-negative effect was also deduced to be the major mechanism of the chimeric genes created by chromosomal translocations. The decrement of RUNX1 activity may be a common underlying cause for RUNX1-related leukemias. However, because these RUNX1 abnormalities per se are insufficient for leukemogenesis, cooperating genetic alteration(s) should be intensively sought for further mechanistic insights and future clinical applications.
- Osato M, Asou N, Abdalla E, et al. Biallelic and heterozygous point mutations in the Runt domian of the AML1/PEBP2αB gene associated with myeloblastic leukemia.Blood. 1999;93:1817–1824.
- Preudhomme C, Warot-Loze D, Roumier C, et al. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2αB gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21.Blood. 2000;96:2862–2869.
- Imai Y, Kurokawa M, Izutsu K, et al. Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis.Blood. 2000;96:3154–3160.
- Song W-J, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytpenia with propensity to develop acute myelogenous leukaemia.Nat Genet. 1999;23:166–175. CrossRef
- Mundlos S, Otto F, Mundlos C, et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia.Cell. 1997;89:773–779. CrossRef
- Nagata T, Gupta V, Sorce D, et al. Immunogobulin motif DNA recognition and heterodimerization of the PEBP2/CBF Runt domain.Nat Struct Biol. 1999;6:615–619. CrossRef
- Nagata T, Werner MH. Functional mutagenesis of AML1/RUNX1 and PEBP2β/CBFβ define distinct, non-overlapping sites for DNA recognition and heterodimerization by the runt domain.J Mol Biol. 2001;308:191–203. CrossRef
- Tahirov TH, Inoue-Bungo T, Morii H, et al. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFβ.Cell. 2001;104:755–767. CrossRef
- Yergeau DA, Hetherington CJ, Wang Q, et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene.Nat Genet. 1997;15:303–306. CrossRef
- Okuda T, van-Deursen J, Hiebert SW, et al. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.Cell. 1996;84:321–330. CrossRef
- Drabkin HA, Erickson P. Down syndrome and leukemia, an update.Prog Clin Biol Res. 1995;393:169–176.
- Gerrard JM, Israels ED, Bishop AJ, et al. Inherited platelet-storage pool deficiency associated with a high incidence of acute myeloid leukaemia.Br J Haematol. 1991;79:246–255. CrossRef
- Ho CY, Otterud B, Legare RD, et al. Linkage of a familial platelet disorder with a propensity to develop myeloid malignancy to human chromosome 21q22.1-22.2.Blood. 1996;87:5218–5224.
- Legare RD, Lu D, Gallagher M, et al. CBFA2, frequently rearranged in leukemia, is not responsible for a familial leukemia syndrome.Leukemia. 1997;11:2111–2119. CrossRef
- Horwitz M, Benson KF, Li FQ, et al. Genetic heterogeneity in familial acute myelogenous leukemia: evidence for a second locus at chromosome 16q21-23.2.Am J Hum Genet. 1997;61:873–881. CrossRef
- Yeoh AEJ, Williams K, Behm F, et al. Somatic mutations of the AML-1 gene are frequent in acute myeloid leukemia with FAB M0 morphology [abstract].Blood. 2000;96:91..
- Huang G, Shigesada K, Ito K, et al. Dimerization with PEBP2β protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation.EMBO J. 2001;20:723–733. CrossRef
- Roulston D, Espinosa R 3rd, Nucifora G, et al. CBFA2(AML1) translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy.Blood. 1998;92:2879–2885.
- Castilla LH, Garrett L, Adya N, et al. The fusion gene Cbfβ-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia.Nat Genet. 1999;23:144–146. CrossRef
- Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.Blood. 1999;93:3074–3080.
- Point Mutations of the RUNX1/AML1 Gene in Sporadic and Familial Myeloid Leukemias
International Journal of Hematology
Volume 74, Issue 3 , pp 245-251
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Point mutation
- Familial leukemia
- Industry Sectors
- Author Affiliations
- 1. Departments of Viral Oncology, Institute for Virus Research, Kyoto University, Kyoto, Japan
- 2. Departments of Genetics and Molecular Biology, Institute for Virus Research, Kyoto University, Kyoto, Japan